Psilocybin-assisted psychotherapy as a rapid-acting treatment for cancer-related depression and anxiety: Evidence from a network meta-analysis
The International Journal of Psychiatry in Medicine · 2025
DOI: 10.1177/00912174251337572 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift The International Journal of Psychiatry in Medicine, 2025. Verfasst von Damian Swieczkowski und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Research and Development, LUXMED Group, Warsaw, Poland. Hauptthemen laut MEDLINE: Anxiety, Depression, Hallucinogens, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Themen: Depression
Abstract (Originalsprache)
Objective
To evaluate psilocybin's efficacy in reducing depressive and anxiety symptoms in cancer patients based on randomized controlled trials (RCTs).
Methods
This systematic review and network meta-analysis (NMA) followed PRISMA and Cochrane Handbook guidelines. PubMed, Embase and Cochrane Library data up to July 2024 were analyzed. Two RCTs met the inclusion criteria. Changes in Beck Depression Inventory (BDI) and State-Trait Anxiety Inventory (STAI) scores were assessed on day 1 and on 2-week follow-up. The risk of bias was evaluated with the Cochrane Risk of Bias Tool 2.0.
Results
Psilocybin significantly reduced BDI scores at day 1 post-administration (MD = 2.26; P = 0.01), though effects were not sustained at 2 weeks. STAI state scores showed substantial reductions at both day 1 (MD = 11.52; P < 0.001) and 2 weeks (MD = 12.66; P < 0.001). STAI trait scores also improved on both day 1 and day 14. The highest psilocybin dose (0.3 mg/kg) was the most effective, with SUCRA values of 87.81% (BDI), 91.58% (STAI state), and 94.2% (STAI trait).
Conclusions
Findings suggest psilocybin may rapidly reduce depressive and anxiety symptoms in cancer patients, but methodological limitations, including the small number of trials, necessitate cautious interpretation. Larger, high-quality RCTs are needed to verify its clinical potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Research and Development, LUXMED Group, Warsaw, Poland.
- Department of Toxicology, Faculty of Pharmacy, Medical University of Gdansk, Gdansk, Poland.
- Department of Psychiatry, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland.
- Department of Public Health, International European University, Kyiv, Ukraine.
- Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, TX, USA.
- Research Unit, Maria Sklodowska-Curie Bialystok Oncology Center, Bialystok, Poland.
ORCID-Profile: Damian Swieczkowski
Zitieren
APA
Swieczkowski, D., Kwaśny, A., Pruc, M., Gaca, Z., Szarpak, L., & Cubała, W. J. (2025). Psilocybin-assisted psychotherapy as a rapid-acting treatment for cancer-related depression and anxiety: Evidence from a network meta-analysis. The International Journal of Psychiatry in Medicine. https://doi.org/10.1177/00912174251337572
Vancouver
Swieczkowski D, Kwaśny A, Pruc M, Gaca Z, Szarpak L, Cubała WJ. Psilocybin-assisted psychotherapy as a rapid-acting treatment for cancer-related depression and anxiety: Evidence from a network meta-analysis. The International Journal of Psychiatry in Medicine. 2025. doi:10.1177/00912174251337572
BibTeX
@article{Swieczkowski2025,
author = {Swieczkowski, Damian and Kwaśny, Aleksander and Pruc, Michal and Gaca, Zuzanna and Szarpak, Lukasz and Cubała, Wiesław J},
title = {Psilocybin-assisted psychotherapy as a rapid-acting treatment for cancer-related depression and anxiety: Evidence from a network meta-analysis},
journal = {The International Journal of Psychiatry in Medicine},
year = {2025},
doi = {10.1177/00912174251337572}
}
EUVIMED